Thryv Therapeutics Announces $30 Million Financing to Launch the ASPIRE-HF Study in Patients with Heart Failure; Wave II Long QT Syndrome Efficacy Cohort Fully Enrolled

• $30 million Series B financing led by InClin, Inc., a global contract research organization, with continued support from existing investors

• ASPIRE-HF, a Phase 2a study of THRV-1268 in heart failure with reduced ejection fraction and QTc prolongation, opens for enrollment in early 2027

• Wave II, a Phase 2/3 study of THRV-1268 in Long QT Syndrome, completes enrollment of its first efficacy cohort, with data expected in early 2027

• Thryv to present new data on SGK1 inhibition in cardiometabolic heart failure in a late-breaking science session at AHA Scientific Sessions 2026

San Francisco, California – November 3, 2026 – Thryv Therapeutics Inc., a clinical-stage biotechnology company developing precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies through its pipeline of potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1), today announced a $30 million Series B financing led by InClin, Inc., a global contract research organization, with continued support from existing investors. The financing follows completion of enrollment of the first efficacy cohort in the Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome and a favorable review of the available Wave II data by the study’s Independent Data Monitoring Committee (IDMC). Proceeds will support advancement of THRV-1268 into ASPIRE-HF (Addressing SGK1-driven Prolonged QT and Impaired REmodeling in Heart Failure), a Phase 2a study in adults with symptomatic HFrEF and QTc prolongation, opening for enrollment in early 2027.

Series B Financing

The Series B financing was led by InClin, Inc., a global contract research organization with operations in San Mateo, California and Sydney, Australia. In recent months, Thryv has worked with InClin to establish clinical operations in Australia, enabling initial patient enrollment in the ASPIRE-HF study early next year. Proceeds will fund the Phase 2a ASPIRE-HF study through a pre-specified analysis of safety and efficacy, including changes in QTc and established biomarkers of heart failure risk. InClin joins as a strategic investor, bringing clinical operating capability alongside capital, together with existing investors Fonds de solidarité FTQ, Amplitude Ventures, Investissement Québec, Lumira Ventures, adMare BioInnovations, CTI Life Sciences Fund, and Alexandria Venture Investments.

ASPIRE-HF

ASPIRE-HF is a Phase 2a, double-blind, randomized, placebo-controlled study evaluating the safety and pharmacokinetics of THRV-1268 and its effects on markers of arrhythmic risk, cardiac function, and cardiac remodeling in adults on GDMT with symptomatic HFrEF and QTc prolongation. Participants will be randomized to one of two dose levels of THRV-1268 or placebo over a 24-week treatment period, with a pre-specified early efficacy evaluation at Week 6.

Additional information will be available at www.aspire-hf.com.

 “ASPIRE-HF is the culmination of years of work to establish SGK1 as a therapeutic target,” said Amy Sehnert, MD, FACC, Chief Medical Officer of Thryv Therapeutics. “Human genetic and preclinical evidence, together with Phase 1 results demonstrating QT interval shortening in obese individuals, supports expanding our clinical program into heart failure. Patients living with HFrEF and a prolonged QTc carry a compounded burden: high residual morbidity on current standard of care, rapid and progressive cardiac failure, electrical instability, and a heightened risk of sudden cardiac death. This financing allows us to begin addressing several drivers of residual risk in this population with the multimodal mechanism of THRV-1268.”

Long QT Syndrome Program Update

The Wave II Phase 2/3 study of THRV-1268 in Long QT Syndrome (NCT07277582) has completed enrollment of its first efficacy cohort, with data expected in early 2027. In the third quarter of 2026, the IDMC reviewed available Wave II safety and pharmacokinetic data and recommended continuation without modification. No serious adverse events have been reported. The Company has submitted a protocol amendment to its U.S. FDA IND to include patients with Long QT Syndrome Type 3, further broadening a study that is now open to participants aged 15 years and older.

Upcoming Presentations at AHA Scientific Sessions 2026

Thryv will present new data at the American Heart Association Scientific Sessions 2026, taking place November 6–9, 2026 at the McCormick Place Convention Center in Chicago, IL.

• Late-Breaking Basic Science
  SGK1 Inhibition, Monotherapy Or In Combination With Incretin Agonism, Targets Residual Risk In Cardiometabolic Heart Failure

• Poster Presentation
  What is the Lived Experience and Symptom Burden of Patients with Long QT Syndrome Type 2 & Type 3? Initial Findings from the myQTwave National Survey

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision therapies for inherited channelopathies, cardiometabolic diseases and cardiomyopathies. SGK1 sits at the intersection of electrical and structural heart disease, where electrical instability drives the inflammation and fibrosis that lead to adverse structural remodeling. Thryv’s lead candidate, THRV-1268, is being evaluated in two clinical trials: Wave II, a Phase 2/3 study in patients with Long QT Syndrome Type 2 (LQT2) and Type 3 (LQT3), and ASPIRE-HF, a Phase 2a study in heart failure with reduced ejection fraction (HFrEF). For more information, visit www.thryvtrx.com.

Investor and Media Contact:

brittany@thryvtrx.com | 514 973 0915 

Thryv Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure

THRV-1268 Maintained a Near-Normal Ejection Fraction and Outperformed Empagliflozin Monotherapy in a Validated Model of Heart Failure; Phase 1 Studies Demonstrated Favorable Safety Profile and QTcF Shortening

San Francisco, California – September 15, 2026 – Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company developing selective SGK1 inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the publication of its new study in JACC: Heart Failure, presenting human genetic, preclinical, and clinical evidence supporting SGK1 inhibition as a novel therapeutic approach for heart failure with reduced ejection fraction (HFrEF). 

Despite advances in guideline-directed medical therapy (GDMT), substantial residual risk persists in HFrEF, with high rates of worsening heart failure, hospitalization, and death. Contemporary data show that approximately 40% of recently hospitalized patients prescribed quadruple GDMT die or are hospitalized for heart failure within 12 months1. Approximately half of patients with advanced heart failure also have QTc prolongation, a biomarker associated with increased arrhythmia susceptibility and worse outcomes, including higher mortality at 6 months2. 

The publication, titled “Genetic, Preclinical, and Clinical Evidence Supports SGK1 Inhibition in Heart Failure,” describes an integrated body of evidence supporting SGK1 as a genetically validated cardiometabolic therapeutic target and THRV-1268 as a potential first-in-class therapy to address the electrical and structural remodeling that drive disease in patients living with HFrEF. 

Key findings include: 

• Human genetic data strongly support SGK1 as a therapeutic target in heart failure. Genetic studies connect SGK1 expression to heart failure risk. Notably, people who naturally carry a genetic variant that lowers SGK1 expression in cardiac tissue have a lower risk of developing heart failure. In diseased human hearts, SGK1 levels are consistently elevated across multiple types of cardiomyopathies. 

• THRV-1268 maintained cardiac function, alone and with empagliflozin, in a validated animal model of heart failure. Treatment preserved systolic function through day 56, with greater and more durable efficacy than empagliflozin monotherapy. THRV-1268 also improved multiple measures of adverse remodeling, reduced natriuretic peptide expression, and reversed pathological inflammatory, fibrotic, and metabolic gene-expression pathways in the heart. In combination with empagliflozin, THRV-1268 maintained a near-normal ejection fraction and attenuated cardiac remodeling, supporting its potential to complement existing standard-of-care therapy. 

• THRV-1268 demonstrated favorable clinical safety and QTcF shortening in individuals with obesity. Across two randomized, double-blind, placebo-controlled Phase 1 studies (NCT06507839, NCT07186946), THRV-1268 was hemodynamically neutral, and well tolerated. In the second study statistically significant QTcF shortening, consistent with cardiac target engagement, was observed. 

“SGK1 sits at the intersection of electrical remodeling and structural remodeling, key drivers of residual risk for lethal arrhythmias and pump failure that remain inadequately addressed in heart failure patients,” said Amy Sehnert, MD, FACC, Chief Medical Officer of Thryv Therapeutics and co-senior author of the publication. "The convergence of human genetic data with the targeted actions of SGK1 inhibition on reversing metabolic, inflammatory, and fibrosis cardiac disease biology seen in HF, in addition to QTc reduction, distinguishes this mechanism from conventional therapies and provides strong rationale to advance THRV-1268 into Phase 2 clinical development." 

The findings support the near-term initiation of ASPIRE-HF (Addressing SGK1-driven Prolonged QT and Impaired REmodeling in Heart Failure), a Phase 2a study of THRV-1268 in patients with symptomatic HFrEF and QTc prolongation who remain at risk of potentially lethal arrhythmias and worsening heart failure despite current therapies. The study is designed to evaluate the safety and PK of THRV-1268 and its effects on arrhythmic risk, cardiac remodeling, and established heart failure biomarkers. 

The article is open access and available at https://www.sciencedirect.com/science/article/pii/S2213177926004075.  

About SGK1 

Serum and glucocorticoid-regulated kinase 1 (SGK1) is a genetically validated cardiometabolic disease node, implicated in key drivers of residual risk in heart failure and cardiomyopathies, including electrical and structural remodeling and pump failure. As a stress-responsive kinase, SGK1 acts across four disease domains relevant to heart failure: myocardial metabolic stress, inflammation, fibrosis, and electrical remodeling. Therapeutic translation of SGK1 biology has historically been limited by the lack of potent, selective inhibitors, a gap Thryv’s proprietary SGK1 inhibitor portfolio was built to address.  

About THRV-1268 

THRV-1268 is an oral, selective SGK1 inhibitor and Thryv Therapeutics’ lead clinical candidate. Across two randomized, double-blind, placebo-controlled Phase 1 studies, THRV-1268 was well tolerated, showed rapid absorption and dose-related exposure, and produced statistically significant QTcF shortening in individuals with obesity, consistent with cardiac target engagement. THRV-1268 is currently being evaluated in WAVE II, a Phase 2/3 clinical study in patients with Long QT Syndrome Type 2.  

About ASPIRE-HF 

ASPIRE-HF is a Phase 2a study of THRV-1268 in adults with HFrEF and QTc prolongation, expected to open for enrollment in Q4 2026. The study will initially enroll at sites in Australia, with potential expansion to additional regions in 2027. Key efficacy endpoints include change from baseline to week 24 in QTcF, NT-proBNP and LVEF with a pre-specified early efficacy evaluation of QTcF change and change in NT-proBNP at week 6. 

About Thryv Therapeutics

Thryv Therapeutics Inc. is a clinical-stage biopharmaceutical company developing a proprietary portfolio of highly potent and selective SGK1 inhibitors for cardiometabolic and CNS diseases of high unmet need. Thryv Therapeutics is headquartered in Montreal, Quebec. For more information, please visit www.thryvtrx.com. 

1. Greene SJ, et al. JAMA Cardiol. 2026;11(3):293-297. doi:10.1001/jamacardio.2025.5339 

2. Vrtovec B, et al. Circulation. 2003;107(13):1764-1769. doi:10.1161/01.CIR.0000057980.84624.95 

Investor and Media Contact:

brittany@thryvtrx.com | 514 973 0915 

Thryv Therapeutics Licenses a New Class of SGK1 Inhibitors from Spain's CSIC and Universidad Autónoma de Madrid, Extending Its Platform into Neurodegenerative Disease

Exclusive worldwide license adds a structurally distinct SGK1 inhibitor scaffold to Thryv's portfolio, with claims spanning neurodegenerative and cardiovascular indications, creating a purpose-built path toward Parkinson's disease, Alzheimer's disease, and related disorders alongside the company's advancing cardiac programs. 

San Francisco, California – September 3, 2026 – Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, today announced that it has entered into an exclusive, worldwide, royalty-bearing patent and know-how license agreement with the Spanish National Research Council (Consejo Superior de Investigaciones Científicas, "CSIC"), the Autonomous University of Madrid (Universidad Autónoma de Madrid, "UAM") and Fundación de la Universidad Autónoma de Madrid ("FUAM"). The agreement became effective on July 1, 2026.  Thryv holds rights across all fields of use and in all territories, with the right to sublicense. 

A second chemical scaffold 

Thryv's existing clinical SGK1 inhibitor candidates were built through independent medicinal chemistry on a single in-licensed scaffold, supported by a library of more than 500 synthesized analogs and a granted selection patent estate. The CSIC/UAM series is a distinct chemotype arising from an entirely separate discovery program, a genuinely new starting point rather than an extension of the existing series.  Adding a second independent series gives Thryv the ability to match chemistry to indication, continuing to optimize its current molecules for cardiac and cardiometabolic diseases while developing compounds designed from the outset to reach the brain. 

Opening the neurodegeneration opportunity 

The licensed invention was developed by research groups with complementary expertise directly relevant to that ambition: the medicinal chemistry group led by Dr. Ana Martínez and Dr. Carmen Gil and the cardiovascular group led by Dr. Eduardo Oliver Pérez at CSIC's Centro de Investigaciones Biológicas Margarita Salas, together with the neurobiology group led by Dr. Isabel Lastres-Becker at UAM's Institute for Biomedical Research and the vascular pharmacology group led by Dr. Ana Briones Alonso at UAM's Department of Pharmacology. 

Activated SGK1 sits at the intersection of several pathways central to neurodegeneration. Published work has implicated the kinase in tau phosphorylation, in the handling of misfolded and aggregating proteins, in neuroinflammatory signaling, and in FOXO- and NRF2-dependent cellular stress responses. This disease biology is directly relevant to Parkinson's disease, Alzheimer's disease and related tauopathies.  

"This is a genuinely exciting day for Thryv," said Debra Odink, President and Chief Development Officer of Thryv Therapeutics. "We have spent years building conviction that SGK1 is one of the most underexploited targets in medicine, and we have proven we can turn that conviction into clinical assets. What this license gives us is a second, independent chemical foundation: new scaffolds, new molecules, and the ability to go after diseases our current chemistry was never designed to reach. Very few companies of our size get to expand their platform this decisively." 

"The work coming out of CSIC and UAM is exceptional, and the teams behind it are among the best in Europe at this intersection of chemistry and neurobiology," Odink added. "Parkinson's and Alzheimer's disease remain two of the hardest problems in drug development. We now have a credible, systematic way to bring SGK1 biology to bear on them, while our cardiac programs continue to move forward at full speed." 

Continuing momentum across the portfolio 

Thryv's lead asset, THRV-1268, is an orally available, selective SGK1 inhibitor currently being evaluated in the WAVE II study in patients with Long QT Syndrome Type 2, with ASPIRE-HF, a Phase 2a study in heart failure with reduced ejection fraction, planned to follow. The newly licensed series is expected to be developed in parallel, with initial characterization work beginning immediately and a first development candidate targeted for nomination in 2027. 

About Thryv Therapeutics

Thryv Therapeutics Inc. is a clinical-stage biopharmaceutical company advancing a proprietary portfolio of selective SGK1 inhibitors. The company pursues mechanisms with strong genetic and clinical validation, beginning in inherited arrhythmia syndromes and heart failure, and now extending into neurodegenerative diseases. Thryv is headquartered in Montréal, Québec. For more information, please visit www.thryvtrx.com. 

Investor and Media Contact:

brittany@thryvtrx.com | 514 973 0915 

Thryv Therapeutics to Participate in UBS, RBC Capital Markets, and Jefferies Healthcare Conferences

Sharing Progress on a Pipeline of First-in-Class SGK1 Inhibitors Targeting High-Risk Cardiovascular Populations 

Montreal, Quebec – May 12, 2026 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited and acquired cardiometabolic diseases, today announced its participation in three upcoming prominent investor conferences in New York City. 

The company looks forward to updating investors on recent pipeline progress, including: 

• Active enrollment in the Wave II Phase 2/3 trial of THRV-1268 in Long QT Syndrome 

• FDA Fast Track designation granted to THRV-1268 

• Anticipated initiation of a Phase 2a study in heart failure with reduced ejection fraction (HFrEF) later this year 

UPCOMING INVESTOR CONFERENCES 

UBS Global Healthcare Conference 2026 

• Dates: May 18–19, 2026 

• Presentation: Monday, May 18, 2026, at 1:15 pm ET 

• Location: New York, NY 

• Format: Company presentation and one-on-one investor meetings 

RBC Capital Markets Global Healthcare Conference 2026 

• Dates: May 19–20, 2026 

• Presentation: Tuesday, May 19, 2026, at 10:30 am ET 

• Location: New York, NY 

• Format: Company presentation and one-on-one investor meetings 

Jefferies Global Healthcare Conference 2026 

• Dates: June 2–4, 2026 

• Location: New York, NY 

• Format: One-on-one investor meetings 

To request a meeting at any of the conferences, please contact: admin@thryvtrx.com.  

About Thryv’s SGK1 Inhibitors 

Thryv Therapeutics is developing a series of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors as first-in-class therapies for rare inherited and acquired cardiometabolic diseases with high unmet need. SGK1 is a genetically validated therapeutic target in heart failure that drives major forms of residual risk and poor outcomes in patients despite current therapies, including chronic inflammation, fibrosis, and arrhythmic risk. In heart tissue, SGK1 activation also adversely affects ion channel function and drives QT interval prolongation, contributing to both congenital and acquired forms of Long QT Syndrome. 

Thryv's lead program is in a Phase 2/3 trial for Long QT Syndrome, a genetic heart rhythm disease, and has the potential to become the first approved disease-modifying therapy for the condition. THRV-1268, an orally administered SGK1 inhibitor being evaluated in the trial, recently received FDA Fast Track designation, with a potential NDA submission anticipated around 2028. Thryv is also expanding its platform into prevalent acquired diseases, including heart failure, cardiomyopathies, and cardiometabolic syndromes. A Phase 2 trial targeting a high-risk segment of heart failure, which affects approximately 1 million U.S. patients, is expected to begin in 2026. 

About Thryv Therapeutics 

Thryv Therapeutics Inc. is a clinical-stage biotech pioneering precision medicine approaches to treating genetic arrhythmia syndromes and acquired cardiometabolic diseases through potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries: 

brittany@thryvtrx.com | 514 973 0915 

Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268

• Patient dosing commenced in Wave II, a multicenter Phase 2/3 study evaluating THRV-1268 in genetically confirmed Long QT Syndrome (LQTS) Type 2; enrollment at leading centers throughout the United States is advancing on track. 

• FDA Fast Track Designation granted for THRV-1268 in LQTS Type 2 and Type 3, supporting expedited development of an investigational therapy targeting QTc reduction and arrhythmic risk in genetically defined LQTS populations. 

San Francisco, California – April 22, 2026 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced key development milestones for its THRV-1268 clinical program: patient dosing has commenced in the Phase 2/3 Wave II clinical study evaluating THRV-1268 in patients with genetically confirmed Long QT Syndrome Type 2, and the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to THRV-1268 for the treatment of Long QT Syndrome Type 2 and Type 3. Enrollment of the Wave II study remains on track with the company’s expectations for delivering initial data in the fourth quarter of 2026. 

Commencement of Patient Dosing in Wave II Phase 2/3 Clinical Study 

Enrollment at leading inherited arrhythmia centers across the United States is under way for the Wave II clinical study (NCT07277582).  Wave II is a multicenter, Phase 2/3 trial enrolling patients with genetically confirmed Long QT Syndrome Type 2. The primary endpoint will assess the safety and efficacy of two dose levels of THRV-1268 over a 12-week period, measured by change in QTcF over six hours, together with evaluations of cardiac rhythm stability, safety, and tolerability. 

Professor Vasanth Vedantham, MD, PhD, at UCSF Health in San Francisco, California, initiated the first of fourteen patients planned in Part A of the Wave II study.  

"The emerging clinical evidence for SGK1's role in cardiac electrophysiology gives me hope that we may finally have a new approach to Long QT Syndrome that addresses the underlying QT interval prolongation.  Initiating Wave II is a meaningful step forward for the potential treatment of patients living with Long QT Syndrome Type 2.  Patients and their families carry an enormous burden – not just the medical complexity of managing arrhythmic risk, but the emotional weight of living with a condition that remains life-threatening despite current therapies," said Vasanth Vedantham, MD, PhD, Professor of Medicine, Cardiac Electrophysiologist and Shashi and Dipanjan (DJ) Deb Endowed Professor in Cardiovascular Genetics, UCSF Health. 

Initially, participants in the Wave II study will receive the study drug as an oral suspension, selected to accelerate data collection for the pediatric formulation, for 12 weeks, with the option to transition to an adult tablet and continue therapy for up to one year. 

FDA Fast Track Designation 

Fast Track Designation is intended to facilitate the development and expedited review of investigational therapies that address serious conditions with unmet medical needs. The designation enables more frequent interactions with the FDA and, if relevant criteria are met, potential eligibility for Rolling Review, Priority Review, and Accelerated Approval. 

“Fast Track Designation represents a meaningful regulatory milestone that reflects the serious and underserved nature of genetically defined Long QT Syndrome,” said Amy Sehnert, MD, FACC, Chief Medical Officer of Thryv Therapeutics. “This recognition by the FDA reinforces our confidence in THRV-1268 and its potential to become the first disease-modifying therapy to specifically target the underlying disease biology of Long QT Syndrome. We are committed to working closely with the Agency as enrollment in the Wave II clinical study advances.” 

For more information, visit www.clinicaltrials.gov or www.wavestudies.com/wave-2. 

About Thryv Therapeutics 

Thryv Therapeutics Inc. is pioneering a precision medicine approach to treating genetic arrhythmia syndromes and cardiometabolic diseases through potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com.    

Disclaimer 

The information stated above was prepared by Thryv Therapeutics and reflects solely the opinion of Thryv Therapeutics. Nothing in this statement shall be construed to imply any support or endorsement of Thryv Therapeutics, or any of its products, by the Regents of the University of California, its officers, agents and employees. Dr. Vedantham will not receive compensation from Thryv Therapeutics. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Launches Pivotal Wave II Phase 2/3 Study in Long QT Syndrome Type 2

• Wave II clinical study will evaluate THRV-1268, Thryv’s oral SGK1 inhibitor, in adults with Long QT Syndrome Type 2. 

• Wave II is informed by the successful Wave I clinical study with LQT-1213 and reinforced by significant QTcF reductions observed in a subsequent clinical study with THRV-1268.  

• Individuals and families affected by Long QT Syndrome are encouraged to follow study progress, share awareness, and learn about participation opportunities via Thryv’s social media channels and at https://www.wavestudies.com/wave-2.  

Montreal, Quebec – January 13, 2026 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the initiation of the Wave II clinical study, a pivotal Phase 2/3 clinical research study in adults diagnosed with Long QT Syndrome Type 2 (LQTS2). Participation in Wave II offers an important opportunity to advance scientific understanding and accelerate the development of new treatment options for people and families affected by Long QT Syndrome. 

“Wave II represents an important step in advancing THRV-1268 toward a potential approved therapy for Long QT Syndrome,” said Dr. Amy Sehnert, Chief Medical Officer, Thryv Therapeutics.  “This rare population lives with a serious and potentially life-threatening condition and has limited treatment options, with no FDA-approved therapies specifically indicated to directly treat Long QT Syndrome by addressing QT prolongation. We look forward to advancing THRV-1268 in this late-stage trial and further evaluating its potential as a therapeutic option for patients.” 

Thryv’s Wave II study builds on the successful completion of the Wave I clinical program (NCT05906732), as well as supportive findings from a more recent Phase 1 clinical study with THRV-1268 (NCT07186946), which together demonstrated the QT-shortening potential of SGK1 inhibition in acquired and congenital Long QT Syndrome Types 2 and 3. In Wave I, treatment with Thryv’s SGK1 inhibitor, LQT-1213, produced clinically meaningful reductions in QTc across patients with LQTS Types 2 and 3, including on top of standard-of-care therapies, while maintaining a favorable safety profile. These results provided clinical proof-of-concept that inhibiting SGK1 can address the underlying electrophysiologic drivers of QT prolongation.  

Wave II is designed to evaluate the safety and efficacy of THRV-1268, an orally administered SGK1 inhibitor, and reflects Thryv’s continued progress toward developing a first-in-class disease-modifying therapy for people living with LQTS2 – a rare inherited condition with no currently approved treatments – that directly addresses the underlying QT prolongation.  Guided by results from the Wave I study, Wave II is a two-part study comprising a 12-week dose-escalation phase (Part A) followed by a 6-week fixed-dose phase (Part B) with a selected dose of THRV-1268. The agreed primary efficacy endpoint is the mean change from baseline in QTc AUC over a given time interval in patients with genetically confirmed LQTS Type 2 with baseline QTc >480 msec. 

In parallel, Thryv’s myQTwave non-interventional study (NCT07075445), continues to enroll individuals with LQTS2 and LQTS3 to further advance understanding of the disease and patient experience. Learn more at www.myQTwave.com.  

U.S. Site Network and Enrollment Timing 

Wave II will recruit across a network of clinical study sites throughout the United States with the first site activated led by Dr Craig McCotter, FACC, FHRS, at Wilmington Health in Wilmington, North Carolina. Additional U.S. sites are expected to be activated over time as recruitment expands. Study details are available on ClinicalTrials.gov (NCT07277582) and at www.wavestudies.com/wave-2. 

About THRV-1268 

Thryv’s extensive non-clinical and clinical research has established strong evidence supporting SGK1 inhibition as a therapeutic approach for Long QT Syndrome (LQTS). This foundational work, generated through the company’s first compound, LQT-1213, has enabled the advancement of THRV-1268 as a best-in-class, optimized SGK1 inhibitor designed for long-term therapy in this chronic, potentially life-threatening disease. THRV-1268 is an investigational, orally administered SGK1 inhibitor being evaluated in the Wave clinical trials for its potential to reduce QT prolongation and support more stable heart rhythms in individuals with LQTS, including LQTS2. 

About Long QT Syndrome Type 2 

Long QT Syndrome Type 2 (LQTS2) is a rare inherited cardiac arrhythmia disorder, characterized by delayed ventricular repolarization, which is reflected as prolongation of the QT interval on electrocardiogram (ECG). QT prolongation increases the risk of potentially life-threatening ventricular arrhythmias, including torsades de pointes and sudden cardiac arrest. Individuals living with Long QT Syndrome face an ongoing risk of cardiac events, and there are currently no approved disease modifying therapies. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic arrhythmia syndromes and cardiometabolic diseases with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants

• Study demonstrated clear target engagement at both tested doses 

• Potential for THRV-1268 to address prolonged QTcF in cardiometabolic diseases 

• Phase 2a ASPIRE-HF study to commence enrollment in 2026 

Montreal, Quebec – December 17, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing novel inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias and cardiometabolic diseases, today announced encouraging results from a recently completed Phase 1 clinical study evaluating THRV-1268 in obese participants (NCT07186946). 

In a dedicated cohort of obese participants (BMI > 30 kg/m2), individuals demonstrated absolute and placebo-corrected QTcF shortening from baseline following a single dose of THRV-1268. This important dataset supports the compound’s differentiated electrophysiologic profile under conditions relevant to cardiometabolic disease (including increased body weight and body mass index). 

The study evaluated pharmacodynamics, pharmacokinetics, safety, and tolerability of THRV-1268 across two single ascending doses (SAD) in obese participants. THRV-1268 appeared to be well tolerated with no serious adverse events (SAEs) reported. Pharmacokinetics (PK) demonstrated that therapeutic exposures were maintained throughout the dosing interval and support twice daily dosing. 

The study included a comparative bioavailability assessment evaluating a new tablet formulation of THRV-1268. Results demonstrated equivalent pharmacokinetic profiles between the tablet and oral suspension.  Based on data from this study, weight-based dose adjustments are not planned for the upcoming Phase 2a ASPIRE clinical trial in heart failure. 

QTc Duration and Clinical Risk in Heart Failure 

QTc duration on electrocardiogram is increasingly recognized as a marker of disease severity and risk of sudden cardiac death in heart failure. Based on its mechanism of action, SGK1 inhibition with THRV-1268 represents a novel therapeutic approach with the potential to address both electrical and structural remodeling in heart failure. Observational studies have shown that prolonged QTc intervals are more common in patients with advanced heart failure compared with those with milder disease. Among patients with more severe heart failure (BNP >400 pg/mL), approximately 50% exhibit QTc prolongation (>440 ms). In this population, prolonged QTc has been shown to independently predict adverse outcomes, including higher rates of all-cause mortality, sudden cardiac death, and pump-failure death. 

Thryv Therapeutics plans to initiate ASPIRE-HF, a Phase 2a clinical trial in 2026, to evaluate THRV-1268 in patients with symptomatic heart failure with reduced ejection fraction (HFrEF) and prolonged QT interval.  

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Strengthens Senior Leadership Team with Appointment of Matt Killeen, PhD, as Chief Business Officer

Montreal, Quebec – December 2, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the appointment of Matt Killeen, PhD, as Chief Business Officer (CBO). 

In this role, Dr. Killeen joins Thryv’s senior leadership team and will be responsible for driving business development, strategic partnerships, corporate and portfolio strategy, and commercialization planning. His leadership will support and align the company’s advancement of its cardiometabolic portfolio and expansion of its SGK1 inhibitor pipeline into novel therapeutic areas where SGK1 plays a significant role.    

Dr. Killeen brings nearly two decades of experience in the biopharmaceutical industry spanning portfolio strategy, business development, commercial strategy, and R&D leadership in advancing first- or best-in-class therapies for cardiometabolic, rare/genetic, and CNS diseases. He founded the precision cardiology therapeutic area at BioMarin, serving as Head of Cardiovascular R&D, where he built an extensive portfolio of genetic therapies for inherited heart diseases through internal R&D and strategic partnerships. Earlier in his tenure at BioMarin, he led portfolio strategy initiatives for the company’s pipeline and commercial portfolio. 

Dr. Killeen later became the first Chief Scientific Officer of Renovacor, advancing its lead gene therapy for genetic cardiomyopathy, growing the pipeline, and helping drive its acquisition by Rocket Pharmaceuticals. Most recently, he served as President of TikkunLev Therapeutics, progressing a novel precision therapy for heart failure. Earlier, he supported three CNS product launches at Biogen and worked as a strategy consultant for global biopharma companies in the U.S. and Europe. 

Across these roles, Dr. Killeen has been committed to discovering, developing, and delivering novel therapies that address the underlying biology of high unmet need diseases.  

“I am thrilled to join Thryv Therapeutics at such a pivotal time in its journey,” said Matt Killeen. “Thryv’s innovative approach to targeting SGK1, a core disease node that drives serious cardiometabolic conditions has the potential to transform the lives of patients living with both genetic and acquired diseases. With a lead program entering late-stage clinical development and a robust pipeline, I look forward to working with Thryv’s talented team to advance these important therapies to patients in need and to help redefine how these serious cardiometabolic diseases are treated.” 

“On behalf of Thryv Therapeutics, I’m thrilled to welcome Matt to our leadership team,” said Paul F. Truex, Chairman & Chief Executive Officer of Thryv. “Matt brings an outstanding track record in strategic business development and operational leadership, and his impact will be pivotal as we accelerate the momentum of our SGK1 inhibitor program.” 

In January, Thryv will begin enrollment in its Phase 2/3 Wave II clinical study for people with Long QT Syndrome Type 2—the first therapeutic registrational study for Long QT Syndrome in a decade. Dr. Killeen’s arrival comes at a pivotal moment for the company, as his scientific and strategic leadership in precision cardiology and cardiometabolic diseases will help guide Thryv’s corporate development priorities, portfolio strategy, and next phase of growth. 

Dr. Killeen earned his PhD in cardiac electrophysiology from the University of Cambridge and was awarded research fellowships at Harvard Medical School and Massachusetts General Hospital. He has authored more than 25 scientific publications and is an elected Fellow of the Heart Rhythm Society, the American College of Cardiology, and the Royal Society of Biology. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Launches myQTwave: A First-of-its-Kind Remote Study Enabling People with Long QT Syndrome to Join Cardiac Research

Montreal, Quebec – December 1, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the launch of myQTwave, a first-of-its-kind, fully remote, app-based observational study designed to capture the lived experience of people with Long QT Syndrome (LQTS). 

The first participants have already enrolled—an important milestone in Thryv’s mission to ensure patient perspectives inform and guide clinical research from the outset. 

“Before we can truly transform treatment for LQTS, we need to understand what patients are experiencing every day. myQTwave represents our commitment to putting patients first—not only in the therapies we develop, but in how we approach clinical research itself,” said Dr. Amy Sehnert, Chief Medical Officer of Thryv. 

A Study Designed Around Real Life 

myQTwave allows adults diagnosed with LQT2 or LQT3 to contribute to cardiac research entirely remotely—using an iPhone and Apple Watch—no clinic visits required. Participants are welcome to join this cardiac research effort from anywhere in the United States. 

The study explores how LQTS affects day-to-day life, collecting both physical and emotional well-being data through: 

• Heart rhythm and activity data via Apple Watch 

• Patient-Reported Outcome (PRO) measures 

• Real-world data gathered during daily routines 

This expanded approach goes beyond traditional clinical metrics—such as ECG findings and cardiac events—to illuminate how LQTS shapes daily decisions, quality of life, and emotional well-being. 

Open for Enrollment 

Adults in the U.S. with a confirmed diagnosis of LQT2 or LQT3 and meeting ECG criteria are eligible. To learn more or determine eligibility, visit www.myqtwave.com or see ClinicalTrials.gov (NCT07075445).

Eligibility Snapshot 

• Adults aged 18 years and older 

• Confirmed genetic diagnosis of Long QT Syndrome Type 2 (LQT2) or Type 3 (LQT3) 

• QT prolongation on electrocardiogram (ECG) 

Note: myQTwave is a non-interventional observational study and does not replace routine clinical care.’ 

The myQTwave study is also featured as a research opportunity through the SADS Foundation, a nonprofit organization dedicated to supporting families affected by inherited arrhythmias. Learn more at: https://sads.org/research/get-involved/thryvlqt/.  

Built With and For the LQTS Community 

myQTwave was developed in collaboration with cardiologists, psychologists, and individuals living with Long QT Syndrome. Patient input informed the study questions, the types of data collected, and how to make remote participation as seamless as possible. 

The study’s Principal Investigator is Samuel Sears, PhD, Professor of Clinical Health Psychology at East Carolina University, a leading expert in quality-of-life research in inherited arrhythmias. 

"Comprehensive care addresses physical, mental, and social health to deliver the best outcomes for patients. Long QT Syndrome is a rare cardiac disease, and understanding the lived patient experience has been incomplete. Our collaborative team designed this best-in-class study to more accurately capture the realities of living with LQTS," said Dr. Sears. 

Part of a Larger Mission 

The launch of myQTwave comes as Thryv advances multiple IND programs. The company has recently opened multiple INDs and is preparing to launch Wave II, a Phase 2/3 registration-directed clinical study in LQTS patients anticipated to begin in early 2026. 

With SGK1 inhibition representing a novel therapeutic approach for LQTS—a condition affecting approximately 1 in 2,500 people—Thryv’s research efforts are aimed at addressing meaningful unmet needs in genetically defined patient populations. 

myQTwave aligns with the FDA’s Patient-Focused Drug Development (PFDD) framework, ensuring that patient voices and experiences help shape future clinical endpoints and treatment strategies. 

Reimagining How LQTS Research Is Done 

Conducted in collaboration with psychologists at East Carolina University, myQTwave is a self-directed, fully remote, non-interventional observational study enrolling adults with LQT2 or LQT3 and QT prolongation. Participants receive an iPhone, Apple Watch, and a user-friendly app featuring questionnaires designed to understand the whole patient—not just clinical markers. 

By integrating connected digital tools, the study will quantify both physical and emotional aspects of living with LQTS, giving patients a direct voice in shaping future research and treatment development. 

About Long QT Syndrome 

Long QT Syndrome (LQTS) is a rare inherited cardiac disorder characterized by delayed ventricular repolarization, seen on an electrocardiogram (ECG) as a prolonged QT interval. This electrical irregularity increases the risk of torsades de pointes, a potentially life-threatening ventricular arrhythmia, often triggered by physical exertion or emotional stress.  

The most common congenital subtypes—LQT1, LQT2, and LQT3—arise from distinct genetic mutations that alter ion channel function and influence arrhythmic risk. LQTS can also be acquired through certain medications that prolong the QT interval and increase arrhythmia risk. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure

Montreal, Quebec – November 19, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the appointment of Amy Rudolph, PhD, to its Board of Directors. Dr. Rudolph brings more than 25 years of leadership experience in the global pharmaceutical industry, with deep expertise spanning discovery, clinical development, medical affairs, and market access.

Dr. Rudolph currently serves as Head of Global Medical Affairs and Cross-TA Medical Affairs at Boehringer Ingelheim, where she leads a global transformation to build a market-leading Medical Affairs organization focused on external engagement, digital/AI integration, evidence generation, advanced analytics, and learning. 

“We are thrilled to welcome Amy Rudolph to our Board of Directors,” said Paul Truex, Chairman and CEO of Thryv Therapeutics. “Her extensive experience in medical affairs, evidence generation, and cross-functional drug development will be invaluable as we progress our SGK1 inhibitor pipeline toward late-stage clinical studies.” 

“We are also deeply grateful to Scott Weiner for his many contributions to the Board of Directors,” added Truex. “We’re pleased that he will remain closely involved with Thryv in an advisory capacity.” 

Prior to joining Boehringer Ingelheim, Dr. Rudolph held leadership roles at Novartis Pharmaceutical Corporation, where she served as Head of HCS (Healthcare Systems) Partnerships in Global Drug Development and Head of Evidence and Launch Excellence in Global Medical Affairs. Earlier in her career, she held key positions at Pfizer Inc., where she was responsible for the atherosclerosis and stroke platforms, early development, and licensing/technology evaluations, and began her scientific career with G.D. Searle/Pharmacia/Pfizer. 

Over the course of her career, Dr. Rudolph has played key roles in the development and launch of multiple cardiovascular therapies, including Inspra, Eliquis, Lipitor, Diovan, Diovan/HCT, Exforge, Tekturna, and Entresto, as well as in the development of Serelaxin and Amturnide. 

Dr. Rudolph earned her Ph.D. in Biochemistry and Molecular Biology from Washington University in St. Louis and is an inventor on 13 patents and numerous scientific publications spanning preclinical research, drug development, and real-world evidence. 

“I am honored to join Thryv Therapeutics’ Board of Directors,” said Amy Rudolph. “Thryv’s science and patient-centered mission resonate deeply with me, and I look forward to supporting the company’s continued progress in addressing serious cardiovascular conditions.” 

Dr. Rudolph joins the Board of Directors as Scott Weiner, who has served as a valued member since 2021, transitions to an observer role. Mr. Weiner will remain on the Board of Directors of the company’s subsidiary, Thryv Therapeutics USA, Inc., while also serving as an advisor to the company. 

About Thryv’s SGK1 Inhibitor Platform 

Thryv Therapeutics is advancing a portfolio of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target the fundamental mechanisms driving electrical and structural remodeling in the heart. THRV-1268, the company’s lead clinical candidate, is a best-in-class, highly selective SGK1 inhibitor with the potential to transform the treatment landscape for Long QT Syndrome (LQTS), heart failure (HF), and atrial fibrillation (AFib)—three serious cardiac conditions with urgent unmet medical needs. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Present at the 2025 American Heart Association Scientific Sessions in New Orleans, LA

Montreal, Quebec – November 5, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced that new preclinical data will be presented at the American Heart Association’s Scientific Sessions 2025, taking place November 8–10 in New Orleans, Louisiana. 

The American Heart Association’s Scientific Sessions bring together global experts to exchange the latest advancements in cardiovascular science, clinical care, and research. Thryv Therapeutics is honored to contribute to this important dialogue with its recent research highlighting the potential of SGK1 inhibition as a novel therapeutic strategy for cardiovascular disease, including heart failure. 

Presentation Details 

Title: The serum and glucocorticoid regulated kinase 1 (SGK1) inhibitor THRV-1268 attenuates hallmarks of heart failure by reducing inflammation and fibrosis beyond sodium/glucose cotransporter 2 inhibition 

• Presenter: Saumya Das, MD, PhD, Co-Director, Resynchronization and Advanced Cardiac Therapeutics Program, Massachusetts General Hospital 

• Date: Sunday, November 9, 2025 

• Time: 10:18–10:23 a.m. CT (Session: 9:15–10:30 a.m.) 

• Location: Clinical Science Zone 2, Poster 22 

• Session: Exploring New Horizons: New Therapeutic Targets in Pulmonary Hypertension 

• Format: Moderated Digital Poster Session 

Title: THRV-1268, a potent and selective serum and glucocorticoid regulated kinase (SGK1) inhibitor, improves adverse cardiac remodeling better than Jardiance® (empagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor in heart failure 

• Presenter: Saumya Das, MD, PhD, Co-Director, Resynchronization and Advanced Cardiac Therapeutics Program, Massachusetts General Hospital 

• Date: Monday, November 10, 2025 

• Time: 10:45–10:50 a.m. CT (Session: 10:45 a.m.–12:00 p.m.) 

• Location: Clinical Science Zone 1, Poster 5 

• Session: Pharmacologic Management of Heart Failure and Cardiomyopathy 

• Format: Moderated Digital Poster Session

Title: Small molecule inhibitors of serum glucocorticoid kinase 1 (SGK1) prevent cardiac structural and functional decline induced in a transverse aortic constriction (TAC) model 

• Presenter: Amy Sehnert, MD, Chief Medical Officer, Thryv Therapeutics Inc. 

• Date: Monday, November 10, 2025 

• Time: 10:59–11:04 a.m. CT (Session: 10:45 a.m.–12:00 p.m.) 

• Location: Clinical Science Zone 1, Poster 5 

• Session: Pharmacologic Management of Heart Failure and Cardiomyopathy 

• Format: Moderated Digital Poster Session 

About THRV-1268 and Thyrv’s SGK1 Inhibitor Program 

THRV-1268 is a best-in-class, highly selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitor with the potential to transform the treatment landscape for Long QT Syndrome (LQTS), heart failure, and atrial fibrillation, three serious cardiac conditions with urgent unmet medical needs. Thryv Therapeutics has open Investigational New Drug (IND) applications to study THRV-1268 in both LQTS and heart failure. 

Thryv is advancing a portfolio of potent and selective SGK1 inhibitors that target the fundamental mechanisms driving electrical and structural remodeling in the heart. SGK1 acts as a central regulator of key pathological processes—including inflammation, fibrosis, and both electrical and structural remodeling—that contribute to the onset and progression of cardiometabolic diseases such as heart failure and atrial fibrillation. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Participate in Upcoming 2025 Healthcare Investor Conferences

Montreal, Quebec – November 3, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced its participation in several prominent healthcare investor conferences this fall, where the company will provide updates on its pipeline and progress in precision cardiovascular medicine.

Wells Fargo Virtual Private Biopharma Symposium 2025 

• Format: Fireside chat and one-on-one investor meetings 

• Date: Wednesday, November 5, 2025 

• Location: Virtual 

Stifel Healthcare Conference 2025 

• Format: Presentation and one-on-one investor meetings 

• Date: Thursday, November 13, 2025, 2:30 pm – 3:15 pm EST 

• Location: Lotte New York Palace Hotel, New York, NY 

Jefferies Global Healthcare Conference 2025 

• Format: Investor meetings 

• Date: Monday, November 17 – Friday, November 21, 2025 

• Location: London, UK 

RBC Healthcare Private Company Conference 2025 

• Format: Fireside chat and one-on-one investor meetings 

• Date: Thursday, December 11, 2025 

• Location: Virtual 

Thryv Therapeutics looks forward to engaging with the investment community to share updates on its SGK1 inhibitor pipeline and clinical programs targeting Long QT Syndrome, atrial fibrillation, and heart failure. 

To arrange a meeting with Thryv Therapeutics during any of the conferences, please contact admin@thryvtrx.com. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

Phase 2/3 Wave II Clinical Study to Begin in 2026

Completion of Financing to Support Registration Program  

Montreal, Quebec – September 17, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its lead compound, THRV-1268. This clearance enables Thryv to initiate the Phase 2/3 WAVE II clinical study in Long QT Syndrome (LQTS) Type 2. 

Details of the Phase 2/3 WAVE II Clinical Study 

The Phase 2/3 Wave II study will evaluate the safety and efficacy of THRV-1268 in patients with LQTS Type 2. The primary endpoint is the mean change from baseline in area under the curve corrected QT interval (QTc AUC (0-6)/6) over six weeks of treatment in adult patients with a baseline QTc >480 milliseconds, regardless of background beta-blocker therapy. 

In parallel with this regulatory milestone, Thryv secured new financing to initiate the Wave II clinical study, marking a significant advancement for THRV-1268 and reflecting strong confidence in Thryv’s differentiated science and leadership in SGK1 inhibition. Thryv’s investors bring deep expertise in cardiovascular development, digital health integration, and global commercialization—providing the capital strength to accelerate THRV-1268 through registrational studies. The financing was supported by Amplitude Ventures, Fonds de solidarité FTQ, Lumira Ventures, Investissement Québec, adMare BioInnovations, and CTI Life Sciences Fund. 

Building on Recent Regulatory Momentum 

This is the second IND clearance for Thryv in recent months, following FDA acceptance of an IND for THRV-1268 in heart failure and atrial fibrillation. Together, these regulatory achievements highlight the broad therapeutic potential of SGK1 inhibition across multiple serious cardiovascular diseases. 

Thryv’s extensive work with its first compound, LQT-1213, provided foundational non-clinical and clinical evidence supporting SGK1 inhibition in LQTS. Building on that success, THRV-1268 is being advanced as a best-in-class, optimized SGK1 inhibitor for LQTS, designed for long-term therapy in this chronic, life-threatening disease. 

“This FDA clearance and the launch of the Wave II Phase 2/3 study early next year represent major milestones in the development of what could become the first approved therapy for Long QT Syndrome,” said Paul Truex, Chairman and CEO of Thryv Therapeutics. “With strong investor support, Thryv is positioned to move rapidly into registration studies. Adults and children with LQTS deserve therapies that not only protect their lives but also allow them to live more fully—we are determined to deliver on that promise.” 

About Long QT Syndrome 

Long QT Syndrome (LQTS) is a rare inherited cardiac arrhythmia condition characterized by delayed ventricular repolarization, reflected on the electrocardiogram (ECG) as a prolonged QT interval. Prolongation of the QT interval increases the risk of torsades de pointes, a potentially life-threatening ventricular tachyarrhythmia. Individuals with LQTS are at greatest risk of arrhythmic events in response to physiological stressors such as exercise or emotional stress. 

The three most common subtypes of congenital LQTS are Type 1, Type 2, and Type 3, each caused by distinct ion channel gene mutations that influence the specific triggers for arrhythmic events. In addition to the congenital forms, LQTS may also be acquired, most often due to exposure to medications that prolong the QT interval and similarly increase the risk of sudden cardiac death. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK-1). For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics Receives FDA IND Clearance of THRV-1268 for Heart Failure and Atrial Fibrillation and Presents SGK1 Inhibition Results Combined with Jardiance in Pressure Overload Model at ESC 2025

Montreal, Quebec – September 8, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced the presentation of preclinical results demonstrating improvements in adverse cardiac remodeling beyond empagliflozin (EMPA) by reducing inflammation and fibrosis mechanisms in heart failure.  These findings were presented by Saumya Das, MD, PhD, Co-Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Massachusetts General Hospital, at the European Society of Cardiology (ESC) Congress 2025, held in Madrid, Spain.

In addition, Thryv is pleased to announce the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to initiate its clinical program in heart failure (HF) and atrial fibrillation.

New Preclinical Data Presented at ESC 2025 

On August 31, 2025, Thryv presented new preclinical data from a pressure overload HF model at ESC Congress. This in vivo study evaluated the effects of THRV-1268, both as a monotherapy and in combination with empagliflozin (Jardiance), an SGLT2 inhibitor, in a transverse aortic constriction (TAC) model. 

Results demonstrated that treatment with THRV-1268, alone or in combination with Jardiance, improved mechanical and structural function over vehicle and Jardiance alone, as measured by left ventricular ejection fraction, end systolic volume, and posterior wall thickness. 

Biomarker analyses demonstrated that THRV-1268 attenuated the dysregulation of pro-inflammatory, pro-fibrotic, and metabolic pathways beyond Jardiance in this model. 

The combination of THRV-1268 with Jardiance represents a promising potential therapeutic strategy for patients with heart failure. A Phase 1 study (NCT06507839) evaluating the safety, tolerability and pharmacokinetics of THRV-1268 demonstrated that the compound was well-tolerated with predictable pharmacokinetics. 

IND Clearance of THRV-1268 for the Heart Failure and Atrial Fibrillation Clinical Programs 

Thryv announced that it has received a Study May Proceed letter from the FDA for its IND application to evaluate THRV-1268 in obese healthy volunteers and screening for that study has begun.  

“This IND clearance represents a significant milestone for Thryv as we transition into mid-stage clinical development,” said Debra Odink, PhD, President and Chief Development Officer of Thryv. “The FDA’s agreement for us to proceed with the Phase 1 clinical investigation is an important step towards the goal of advancing THRV-1268 into Phase 2 proof of efficacy studies, where we aim to demonstrate its potential as a novel, mechanism-based therapy for patients living with heart failure and atrial fibrillation.” 

The role of SGK1 inhibition in mediating beneficial structural and electrical remodeling well suits the company’s plans to initiate the Phase 2 proof of efficacy Aspire study in heart failure and obesity-associated paroxysmal atrial fibrillation in 2026.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK-1). For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Present at the 2025 European Society of Cardiology Congress in Madrid, Spain

Montreal, Quebec – August 25, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company, today announced that Dr. Saumya Das will present compelling new preclinical results on its lead compound, THRV-1268, at the upcoming European Society of Cardiology (ESC) Congress 2025, taking place August 29 – September 1, 2025, in Madrid, Spain.  In addition to Thryv’s data presentation, research conducted by the European Joint Programme on Rare Diseases (EJPRD) will also be featured at ESC 2025. The collaborative research with one of Thryv’s SGK1 inhibitors provides extensive evidence for the role of SGK1 inhibition in Long QT Syndrome (LQTS), through its effect on late sodium current and action potential duration in preclinical models of LQTS. 

THRV-1268 is a best-in-class, highly selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitor with the potential to transform the treatment landscape for Long QT Syndrome (LQTS), heart failure, and atrial fibrillation—three serious cardiac conditions with urgent unmet medical needs.  

Thryv’s presentation will spotlight results from a Transaortic Constriction (TAC) preclinical model with both THRV-1268 and Jardiance (empagliflozin) – an SGLT2 inhibitor currently used as part of guideline directed medical therapy for individuals with heart failure. These breakthrough findings for both SGK1 monotherapy and in combination with SGLT2i inhibition strengthen the scientific case for SGK1 inhibition as a powerful strategy against inflammation and fibrosis-driven cardiac remodeling—critical pathways in heart failure and related disorders. 

Presentation Details 

• Title: THRV-1268, a novel and potent SGK1 inhibitor, improved adverse cardiac remodeling beyond empagliflozin, an SGLT2 inhibitor, by reducing inflammation and fibrosis mechanisms in heart failure 

• Presenter: Saumya Das, MD, PHD, Co-Director, Resynchronization and Advanced Cardiac Therapeutics Program, Massachusetts General Hospital 

• Date: Saturday, August 30, 2025 

• Time: 1:15 – 2:00 p.m. CET 

• Location: Station 4 (Research Gateway) 

• Format: Moderated e-Poster 

• Session Link: SGLT2 Inhibitors in Heart Failure Prevention and Treatment – ESC365

Presentation Details 

• Title: SGK1 inhibition shortens action potential duration and exerts anti-arrhythmic effects in LQT3 mice and LQT2 rabbits by reducing enhanced late sodium current 

• Presenter: Simona Casini, Amsterdam University Medical Centre (AUMC) 

• Date: Sunday, August 31, 2025 

• Time: 1:25 – 2:15 p.m. CET 

• Location: Science Box 4 (Research Gateway) 

• Format: Abstract Session 

• Session Link: Molecular and Cellular Drivers of Arrhythmia – ESC365

About Thyrv’s SGK1 Inhibitors 

Thryv Therapeutics is advancing a series of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target the underlying causes of electrical and structural remodelling which leads to cardiac conditions such as Long QT Syndrome, heart failure, and atrial fibrillation.  

In cardiometabolic diseases, SGK1 plays a critical role in driving pathological processes, including inflammation, structural remodeling, electrical remodeling and fibrosis, which can play a significant role in the development of heart failure and atrial fibrillation.               

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK-1). For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Share Recent Clinical Results and Participate in Upcoming Healthcare Investor Conferences

Montreal, Quebec – May 13, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced its participation in two upcoming prominent investor conferences in New York City. The company will share recent clinical results in Long QT Syndrome presented at the 2025 Heart Rhythm Society Annual Meeting and recent developments for its pre-clinical and clinical programs for both heart failure and atrial fibrillation. 

Clinical Results Presented at HRS 2025 

On April 27, 2025, Thryv presented new clinical data from Part 2 of the Wave I study at the Heart Rhythm Society (HRS) Annual Meeting. The study enrolled adult patients with genetically confirmed Long QT Syndrome Type 2 or Type 3 who received oral doses of LQT-1213 at either 7 mg TID or 16 mg TID for 2⅓ days (seven total doses). LQT-1213 appeared to be generally well-tolerated across both dose groups. 

Clinically meaningful and statistically significant reductions in QTcF interval were observed in the high dose cohort. Key regulatory endpoints for Long QT Syndrome – such as QTcF area under the curve (AUC) and maximal peak-to-trough effects – demonstrated mean reductions of up to 11 milliseconds (p=0.028) for QTcF AUC. In a subsequent analysis of peak-to-trough changes, the 53 milliseconds (p<0.0001) reduction in QTc is consistent with publications of other drugs studied but not approved for this indication.  

These results provide important clinical proof-of-concept that LQT-1213 – part of Thryv’s series of highly selective SGK1 inhibitors – may offer a disease-modifying approach and lay the foundation for continued clinical development of SGK1 Inhibitors for Long QT Syndrome.                                          

Upcoming Investor Conferences 

RBC Capital Markets Global Healthcare Conference 2025 

• Dates: May 20–21, 2025 

• Fireside Chat: Wednesday, May 21, 2025, at 9:30 am EST (Track IV – 2nd Floor) 

• Location: InterContinental New York Barclay, New York, NY 

Thryv Therapeutics will participate in a fireside chat and host one-on-one meetings with investors about its future program plans and Series B financing throughout the conference. 

Jefferies Global Healthcare Conference 2025 

• Dates: June 3–5, 2025 

• Location: New York Marriott Marquis, New York, NY 

Thryv Therapeutics will participate in one-on-one investor meetings. 

To request a meeting at either conference, please contact: admin@thryvtrx.com  

Study Highlights 

Wave I is a multi-part, first-in-human proof-of-concept clinical study designed to evaluate the safety, pharmacokinetics (PK), and efficacy of LQT-1213 in patients with both acquired and congenital forms of Long QT Syndrome. 

• Part 1 results were presented at the American College of Cardiology’s Annual Scientific Session in March 2024. Read the full poster here. 

• Part 2 is a single-blind, placebo run-in, multiple-dose safety study in participants with cLQTS Type 2 or 3.  Results were presented at the Heart Rhythm Society Annual Meeting in April 2025. Read the full abstract here. 

More about the Wave I study (Parts 1 and 2) can be found at: https://www.clinicaltrials.gov/study/NCT05906732. 

About Thyrv’s SGK1 Inhibitors 

Thryv Therapeutics is advancing a series of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target the underlying causes of electrical and structural remodelling which leads to cardiac conditions such as Long QT Syndrome, heart failure, and atrial fibrillation.  

In heart tissue, SGK1 has been shown to adversely affect ion channel function and surface expression. Its activation is implicated in prolongation of the QT interval, contributing to both congenital and acquired forms of LQTS and adverse outcomes in cardiometabolic diseases such as heart failure and atrial fibrillation.  Inhibition of SGK1 may address the root cause of electrical dysfunction and offer a disease-modifying therapy by targeting both electrical and structural remodeling of cardiomyocytes. 

About Long QT Syndrome (LQTS) 

Long QT Syndrome (LQTS) is a disorder of the heart’s electrical system that delays ventricular repolarization, prolonging the QT interval on an ECG. This can lead to torsade de pointes — a potentially fatal arrhythmia — and sudden cardiac death. 

LQTS can be congenital, caused by mutations in cardiac ion channel genes (commonly LQT1, LQT2, or LQT3), or acquired, resulting from medications or medical conditions. Congenital LQTS is a rare orphan disease, affecting approximately 1 in 2,000 people worldwide. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK-1). For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Present at the 2025 Heart Rhythm Society Annual Meeting in San Diego, CA

Montreal, Quebec – April 15, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Heart Rhythm Society (HRS) Annual Meeting. The conference will be held at the San Diego Convention Center from April 24-27, 2025.

Preceding the conference on Wednesday, April 23rd, Dr. Amy Sehnert, Chief Medical Officer at Thryv Therapeutics, will speak at the Stanford Biodesign New Arrhythmia Technologies Retreat in San Diego. Her presentation, titled “Small Molecules for Arrhythmia Therapy,” will highlight emerging approaches to rhythm management. 

The HRS Annual Meeting brings together leading scientists, clinicians, and industry professionals to discuss the latest advancements in heart rhythm disorders. The event serves as a key platform for unveiling cutting-edge research and fostering collaborations that drive innovation in patient care. 

Thryv Therapeutics is honored to contribute to this important dialogue by presenting new clinical data from the Wave I, Part 2 study, which evaluates the effects of SGK-1 inhibition in patients with Long QT Syndrome Type 2 and Type 3. 

Presentation Details 

• Title: SGK-1 Inhibition with LQT-1213 Significantly Reduces the QTcF in Patients with Congenital Long QT Syndrome in the Wave I, Part 2 Study 

• Presenter: Philip Sager, MD 

• Date: Sunday, April 27, 2025 

• Time: 8:24 – 8:34 a.m. PST 

• Location: Oral Abstract Hub 4 – Sails Pavillion, SDCC

To schedule a meeting with a Thryv representative at the HRS Annual Meeting, email admin@thryvtrx.com.  

For more information about the HRS Annual Meeting, visit: https://heartrhythm.com/ 

More about the Wave I (Parts 1 and 2) can be found at: https://www.clinicaltrials.gov/study/NCT05906732. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat Long QT Syndrome, heart failure and atrial fibrillation with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK-1). For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Participate in the 2025 Piper Sandler Virtual Cardio Day

Montreal, Quebec – March 27, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Piper Sandler Virtual Cardio Day on April 1, 2025.

Thryv’s leadership team will take part in a fireside chat from 11:30–11:55 a.m. ET to discuss the company’s latest advancements in cardiovascular research. The discussion will focus on Thryv’s progress in developing novel SGK1 inhibitors for the treatment of Long QT Syndrome, heart failure, and atrial fibrillation. 

Thryv Therapeutics Fireside Chat 

Date: April 1, 2025 

Time: 11:30–11:55 a.m. ET 

Participants: 

• Paul Truex, Chairman and CEO 

• Amy Sehnert, MD, Chief Medical Officer

The Piper Sandler Virtual Cardio Day is an invitation-only event for Piper Sandler clients. For additional details or to request access to the webcast, please contact your Piper Sandler representative.

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) to treat Long QT Syndrome, heart failure and atrial fibrillation. For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference in Miami, FL

Montreal, Quebec – February 3, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its participation in the 2025 Leerink Partners Global Healthcare Conference. The event is set to take place from March 10-12, 2025, at the W Hotel South Beach in Miami, Florida.

The Leerink Partners Global Healthcare Conference is a premier gathering of industry leaders, investors and innovators, providing a platform to explore the latest advancements and trends shaping the healthcare sector.

Thryv Therapeutics will participate in one-on-one meetings on Wednesday, March 12, 2025. 

To schedule a meeting during the conference, please contact us at admin@thryvtrx.com. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv Therapeutics is pioneering a precision medicine approach to develop potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) to treat Long QT Syndrome, heart failure and atrial fibrillation. For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915

Thryv Therapeutics to Attend the 2025 J.P. Morgan Healthcare Conference in San Francisco

Montreal, Quebec – December 18, 2024 – Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is pleased to announce its attendance at the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco, CA. 

The J.P. Morgan Healthcare Conference is the industry’s leading global investment forum, bringing together top executives, investors, and innovators across the healthcare ecosystem. With over 500 healthcare companies presenting, the event showcases groundbreaking advancements in biotechnology, pharmaceuticals, and healthcare technologies. 

To arrange a meeting with Thryv Therapeutics during the conference, please contact us at admin@thryvtrx.com. 

About Thryv Therapeutics Inc.

Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada, pioneering a precision medicine approach to treating heart failure, atrial fibrillation, Long QT Syndrome and other cardiometabolic and cardiorenal diseases with potent and highly selective serum glucocorticoid inducible kinase 1 (SGK1) inhibitors.  Numerous animal models have demonstrated that activation of SGK1 leads to inappropriate electrical and structural remodeling of the heart contributing to adverse outcomes in heart failure, atrial fibrillation, and genetic channelopathies, such as Long QT Syndrome.  For more information, please visit www.thryvtrx.com. 

Media Inquiries

brittany@thryvtrx.com | 514 973 0915